KOSDAQBiotech & Pharma053030

Binex

₩6,780▼ 0.29%2026-11-18 close
Market Cap
₩221.6B
Turnover
₩600M
Volume
80K
Shares out.
32.7M
PER
—
PBR
1.2×
EPS
-₩843
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Loss narrowing and a Q3 profit turn; Osong expansion is the test

Binex narrowed its operating loss in 2025 and returned to operating profit in Q3 2026, but wider losses in Q1–Q2 2026 and negative operating cash flow remain open issues for this biopharma CDMO.

  1. 1

    2025 revenue was KRW 168.5 billion, up 29.5% year on year, and the operating loss narrowed to KRW 4.53 billion from KRW 30.8 billion in 2024.

  2. 2

    Q3 2026 revenue was KRW 51.5 billion, with operating profit of KRW 1.46 billion and attributable net income of KRW 1.45 billion.

  3. 3

    The operating loss widened to KRW 8.97 billion in Q1 2026 and KRW 9.15 billion in Q2 2026, and attributable net losses over the last four quarters total KRW 26.9 billion.

  4. 4

    Bio CDMO sales reached KRW 81.7 billion in 2025, up 79.0%, lifting the segment to 48.5% of total revenue according to press reports.

  5. 5

    The Osong plant expansion and EMA and FDA cGMP inspections are the next checkpoints, and the next periodic report is the 2026 annual report.

02

Business structure

Binex runs two businesses: chemical (synthetic drug) sales and biopharmaceutical contract development and manufacturing (CDMO). Press reports said synthetic drugs accounted for about 66% of total revenue in Q3 2024, and the bio segment's weight has grown since.

Bio CDMO sales reached KRW 81.7 billion in 2025, up 79.0%, and its share of total revenue rose from 35.1% to 48.5%, according to press reports.

Celltrion is the main bio customer: commercial production of its Aptozma biosimilar (CT-P47) at the Songdo plant became full-scale from the second half of 2025, and two PPQ (process performance qualification) runs were carried out at the Osong plant.

A company analysis page cites supply contracts of KRW 16 billion with a global pharma company and a KRW 20 billion commercial supply contract. Binex is classified as a small-to-mid-sized CDMO that targets multi-product, small-batch work and mid-sized volumes, in contrast to the large CDMO players.

Its production sites are Songdo and Osong, and IBK Investment & Securities reported in March 2026 that the Songdo shutdown cycle was changed from once a year to once every three years. Brokerage research has said the chemical segment's growth is limited by drug price cuts. Expansion of the bio segment is becoming the axis that changes the company's earnings structure.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩45.4B₩200M0.5%
2025Q4₩38.8B-₩6.3B−16.3%
2026Q1₩35.3B-₩9B−25.4%
2026Q2₩37.8B-₩9.2B−24.2%
2026Q3₩51.5B₩1.5B2.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩156.7B₩17.2B₩12.4B11.0%6.5%55.2%
2023₩154.8B₩1B₩4.7B0.7%2.6%41.7%
2024₩130.1B-₩30.8B-₩35.1B−23.6%−19.3%53.8%
2025₩168.5B-₩4.5B-₩3.2B−2.7%−1.7%66.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a filed basis, annual revenue moved from KRW 156.7 billion in 2022 to KRW 154.8 billion in 2023 (down 1.2%) and KRW 130.1 billion in 2024 (down 16.0%), before recovering to KRW 168.5 billion in 2025 (up 29.5%). 2025 was the largest year of 2022–2025 and 2024 the smallest.

Operating profit fell from KRW 17.2 billion in 2022 to KRW 1.04 billion in 2023 (down 93.9%), then turned into an operating loss of KRW 30.8 billion in 2024. The 2025 operating loss of KRW 4.53 billion was smaller. Operating losses were recorded in 2024 and 2025, two consecutive loss years.

The operating margin was 11.0% in 2022, 0.7% in 2023, -23.6% in 2024 and -2.7% in 2025.

Attributable net income fell from KRW 12.4 billion in 2022 to KRW 4.67 billion in 2023 (down 62.5%), then became an attributable net loss of KRW 35.1 billion in 2024 and narrowed to an attributable net loss of KRW 3.23 billion in 2025.

Net income including non-controlling interests was a net loss of KRW 3.29 billion in 2025.

The company attributed the 2025 improvement to sales growth in its pharmaceutical business, easing of past drug price cut effects and streamlined costs, while the bio unit said a temporary revenue stall tied to FDA approval preparation ended and commercial project production ramped up (as reported in March 2026).

Quarterly, Q3 2025 operating profit was KRW 242 million, but Q4 2025 swung to an operating loss of KRW 6.34 billion, and press reports linked this to the Songdo plant shutdown.

Revenue bottomed at KRW 35.3 billion in Q1 2026 and then rose to KRW 37.8 billion in Q2 and KRW 51.5 billion in Q3, two consecutive quarters of growth. The operating loss widened to KRW 8.97 billion in Q1 and KRW 9.15 billion in Q2, then Q3 posted operating profit of KRW 1.46 billion, up 501.8% year on year.

The attributable net loss reached KRW 15 billion in Q2 2026 before Q3 attributable net income of KRW 1.45 billion. Attributable net losses over the last four quarters total KRW 26.9 billion. Operating cash flow went from KRW 17.1 billion in 2022 to -KRW 9.43 billion in 2024 and -KRW 23.3 billion in 2025.

The debt ratio rose from 55.2% in 2022 to 66.1% in 2025. At the end of 2025, total equity was KRW 187.5 billion, of which attributable equity was KRW 187.3 billion, and total liabilities were KRW 124 billion.

05

Industry analysis

Demand for biopharmaceutical CDMO services is tied to supply chain restructuring by global pharma companies, and the company has said it is preparing to capture the resulting new order opportunities.

Simplified clinical requirements for biosimilars are creating product diversification opportunities, according to market commentary. IBK Investment & Securities said in a March 2026 report that the simplification centered on the US and Europe could benefit small-to-mid-sized CDMOs over the medium to long term.

The same report stressed that building a track record through orders from large domestic bio companies matters. A 2025 brokerage analysis noted the possibility of winning new customers if the BIOSECURE Act is reintroduced.

Celltrion and other biosimilar makers sit at the center of downstream demand, and Binex's role is growing in their commercial production stages. Against peers, large CDMOs such as Samsung Biologics compete on very large production scale, while Binex focuses on mid-sized orders and multi-product manufacturing.

However, its customer base and commercial production history are shorter than those of larger companies, so accumulating orders takes time.

Its position in the cycle is tied to the recovery of biopharmaceutical manufacturing demand, and the earnings contribution depends on how quickly projects move into commercial volume.

06

Outlook

The company is pushing to double Osong plant capacity and has said it plans to respond to new order opportunities from global supply chain restructuring (per a June 2026 company profile). IBK Investment & Securities said in a March 2026 report that Osong expansion was expected to proceed through Q4 2026.

The same report said plant inspections for EMA and FDA cGMP approval were likely to become visible in the second half of the year. Another view holds that the 2025 FDA cGMP inspection passed without observations, so inspection information differs by report and date.

A company analysis page summarized a plan to keep revenue growing from the second half of 2026 once Osong expansion and cGMP approval are complete. Commercial production of the Celltrion Aptozma biosimilar continues at Songdo, and press reports said one additional PPQ order is slated for production at Osong.

With the shutdown cycle changed to once every three years, equipment utilization volatility is expected to be lower than before. The next checkpoints are whether the Osong expansion is completed and the outcome of the cGMP inspections.

The 2026 annual report will contain the full-year confirmed figures including Q4 2026, and its operating margin becomes the reference point. How the report explains the widening quarterly losses in the MD&A section is also a item to check.

07

Valuation

PER
—
PBR
1.2×
ROE
-15.3%
EPS
-₩843
BPS
₩5,118
Dividend per share
₩0

Valuation is better read through book-value measures than earnings multiples, given the filed results. Because attributable net losses have continued over the last four quarters, a price-to-earnings ratio cannot be calculated on trailing earnings.

The price-to-book ratio fell from the 4x range at the end of September 2024 to the 2x range at the end of September 2025, and as of November 14, 2026 it remains above 1x.

Attributable equity was KRW 187.3 billion of the KRW 187.5 billion total equity at the end of 2025, so the stock still trades at a premium to book value. Dividend yield is below the industry average. The debt ratio rose from 55.2% in 2022 to 66.1% in 2025, which makes leverage a relevant comparison point.

Whether the premium to net assets holds depends on how quickly operating results move from loss to stable profit.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Narrower losses and a Q3 profit turn

The operating loss narrowed from KRW 30.8 billion in 2024 to KRW 4.53 billion in 2025, and Q3 2026 posted operating profit of KRW 1.46 billion. Q3 revenue of KRW 51.5 billion came after two consecutive quarters of growth. The most visible directional change is the shift in the earnings structure from loss to profit.

Expansion and order-book plans

The company is pushing to double Osong plant capacity. A company analysis page summarized a KRW 16 billion supply contract and a KRW 20 billion commercial supply contract. Once the expansion is complete, capacity for commercial volume would increase.

Regulatory credentials and a large-customer base

One assessment says the 2025 FDA cGMP inspection passed without observations. Commercial production of the Celltrion Aptozma biosimilar continues at Songdo. Bio CDMO sales reached KRW 81.7 billion in 2025, up 79.0%, and the segment reached 48.5% of total revenue.

09

Bear factors

Wider losses in Q1–Q2 2026

The operating loss widened to KRW 8.97 billion in Q1 2026 and KRW 9.15 billion in Q2. The attributable net loss reached KRW 15 billion in Q2. The Q3 profit is a single-quarter result, and attributable net losses over the last four quarters total KRW 26.9 billion.

Cash burn and rising leverage

Operating cash flow was -KRW 9.43 billion in 2024 and -KRW 23.3 billion in 2025. The debt ratio rose from 55.2% in 2022 to 66.1% in 2025. Capital expenditure in 2025 was about KRW 21.2 billion, so investment needs are weighing on cash flow.

Plant downtime and customer concentration

The Q4 2025 swing to an operating loss was linked by press reports to the Songdo plant shutdown. Celltrion's Aptozma commercial production was the main driver of bio revenue growth. A change in one customer's production schedule could cause larger quarterly revenue swings.

10

Risk factors

Plant utilization and shutdowns

The Songdo shutdown was linked by press reports to the swing to an operating loss in Q4 2025. Although the cycle was changed to once every three years, the downtime is longer, so quarters with lower utilization could add earnings volatility. A delay in the Osong expansion would also push back the timing of larger commercial volumes.

Customer concentration

Press reports said Celltrion's Aptozma commercial production drove bio revenue growth in 2025. Until new customer orders accumulate, dependence on a single customer remains high. A change in that customer's launch timing or production plan would affect revenue flow.

Financing and balance sheet

Operating cash flow was -KRW 23.3 billion in 2025. Financing cash flow was a KRW 33.2 billion inflow in 2025, indicating reliance on external funding for investment. With the debt ratio at 66.1%, the terms of any additional financing could shape the balance sheet burden.

11

What to watch next

  1. By late December 2026

    Completion of the Osong plant expansion. A March 2026 report expected work to run through Q4, and completion would be a marker for commercial line capacity.

  2. By late December 2026

    Results of the EMA and FDA cGMP plant inspections. Passing these could widen the scope of global customer orders.

  3. By late December 2026

    Progress of Aptozma commercial production at Songdo and the additional PPQ run at Osong. Whether these volumes run is the benchmark for Q4 revenue.

  4. By end-March 2027

    The 2026 annual report on DART. The confirmed full-year figures including Q4 2026, the operating margin, operating cash flow and the debt ratio are the checkpoints.

12

Overall view

Binex narrowed its 2025 operating loss and returned to operating profit in Q3 2026, so its earnings structure is changing direction. Bio CDMO sales rose 79.0% to KRW 81.7 billion in 2025, shifting the business mix toward bio.

On the other side, operating and attributable net losses widened in Q1 and Q2 2026, and attributable net losses over the last four quarters total KRW 26.9 billion. Negative operating cash flow and a rising debt ratio are financial items to track.

The Osong expansion, the cGMP inspections and the 2026 annual report are the next checkpoints. The stock still trades at a premium to book value, and the valuation picture depends on how steadily results move from loss to profit.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. corvesting.com
  3. jasoseol.com
  4. comp.fnguide.com
  5. medipana.com
  6. dailyinvest.kr
  7. m.news.nate.com
  8. newsfc.co.kr
  9. pharm.edaily.co.kr
  10. investing.com
  11. tradingkey.com
  12. investors.nexxen.com
  13. financialcontent.com
  14. globenewswire.com
  15. news.skhynix.com
  16. edaily.co.kr
  17. thebionews.net

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis